Klinikum Braunschweig;
Seraph 100 binds SARS-CoV-2, the virus that causes COVID-19. Clinicians have anecdotally reported a reduction in inflammatory markers such as IL-6, d-dimers, and ferritin. Other anecdotal observations include improved hemodynamic stabilization, reduction of vasopressors and fractionally inspired oxygen, and avoidance or reduced time of mechanical ventilation.
* Seraph 100 is the first device with an indication to reduce pathogens in the bloodstream in adjunction to antibiotic therapy
* It reduces a broad-spectrum of drug-susceptible and drug- resistant pathogens * It is able to be used as an early intervention prior to pathogen identification
* Bacteria do not develop resistance to Seraph 100 due to its novel biomimetic binding surface Seraph 100 has broad applications for the safe reduction of drug-susceptible and drug-resistant pathogens that are in the bloodstream, including secondary bacterial or fungal infections that often occur during COVID-19.